A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 29; p. viii334
Main Authors: Lee, J.-M., Annunziata, C.M., Houston, N., Kohn, E.C., Lipkowitz, S., Minasian, L., Nichols, E., Trepel, J., Trewhitt, K., Zia, F., Zimmer, A.D.S.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-10-2018
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy285.145